Genetically prioritized druggable targets for amyloid-β pathology highlight ACE as a therapeutic candidate in Alzheimer's disease
Journal of Alzheimer’s Disease · 2026-07 · 112 (2) · 1016-1025
DOI: 10.1177/13872877261454540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 29.05.2026. Verfasst von Jun Pyo Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Peptidyl-Dipeptidase A, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Ministry of Health & Welfare, Republic of Korea.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer's disease (AD) is characterized by a neuropathological cascade that begins with amyloid-β (Aβ) deposition. The recent success of disease-modifying drugs targeting Aβ has demonstrated that modulating amyloidopathy can yield clinical benefits, underscoring the need for additional drugs affecting amyloid pathology.
Objective
To identify novel drug targets associated with Aβ accumulation in AD using Mendelian randomization (MR) analysis of the druggable genome.
Methods
We performed MR analysis on expression quantitative trait loci (eQTLs) of the druggable genome in relation to Aβ accumulation using summary-data-based MR (SMR). Blood eQTL data were obtained from the eQTLGen consortium, and brain eQTL data from BrainMeta and PsychENCODE, while Aβ positron emission tomography (PET) genome-wide association study data were derived from 11,816 non-Hispanic White participants across 13 cohorts. Co-localization analysis was conducted to enhance the reliability of the MR results, and additional validation was performed using blood and brain protein quantitative trait loci (pQTLs) as instrumental variables.
Results
The SMR and co-localization analyses revealed causal associations between the druggable genome and Aβ accumulation, with APH1B identified in blood eQTL data and ACE , APH1B , and CR1 identified in brain eQTL data. Further analysis using pQTL data confirmed causal associations for ACE and CR1, with ACE showing a negative association with Aβ PET uptake.
Conclusions
These findings highlight potential target genes for AD treatment, and the protective effect of ACE against amyloid pathology suggests that alternative medications to ACE inhibitors may be preferred for blood pressure management in the context of AD. Overall, our study demonstrates the potential of MR to facilitate drug repurposing for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
- Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea.
- Department of Health Sciences and Technology, Sungkyunkwan University, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, Republic of Korea.
- Department of Clinical Research Design & Evaluation, Sungkyunkwan University, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, Republic of Korea.
- Center for Clinical Epidemiology, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
ORCID-Profile: Hyunwoo Lee, Sohyun Yim, Han-Na Kim
Förderung
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Kim, J. P., Lee, H., Kim, B. H., Kang, H., Shin, D., Yim, S., Kim, S., Seo, S. W., & Kim, H. N. (2026). Genetically prioritized druggable targets for amyloid-β pathology highlight ACE as a therapeutic candidate in Alzheimer's disease. Journal of Alzheimer’s Disease, 112(2), 1016-1025. https://doi.org/10.1177/13872877261454540
Vancouver
Kim JP, Lee H, Kim BH, Kang H, Shin D, Yim S, et al. Genetically prioritized druggable targets for amyloid-β pathology highlight ACE as a therapeutic candidate in Alzheimer's disease. Journal of Alzheimer’s Disease. 2026;112(2):1016-1025. doi:10.1177/13872877261454540
BibTeX
@article{Kim2026,
author = {Kim, Jun Pyo and Lee, Hyunwoo and Kim, Bo-Hyun and Kang, Heekyoung and Shin, Daeun and Yim, Sohyun and Kim, Seonghyeon and Seo, Sang Won and Kim, Han-Na},
title = {Genetically prioritized druggable targets for amyloid-β pathology highlight ACE as a therapeutic candidate in Alzheimer's disease},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
volume = {112},
number = {2},
pages = {1016--1025},
doi = {10.1177/13872877261454540}
}
EUVIMED